Phosphodiesterase-5 Inhibitors and Survival in Men With Coronary Artery Disease

J Am Coll Cardiol. 2021 Mar 30;77(12):1551-1553. doi: 10.1016/j.jacc.2021.02.021.

Authors

Renke Maas¹, Roman N Rodionov²

Affiliations

¹ Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany. Electronic address: renke.maas@fau.de.
² Division of Angiology, Department of Internal Medicine III, University Center for Vascular Medicine, Technische Universität Dresden, Dresden, Germany; College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.

PMID: 33766261
DOI: 10.1016/j.jacc.2021.02.021

No abstract available

Keywords: alprostadil; erectile dysfunction; phosphodiaesterase inhibitors; sildenafil; surival.

Publication types

Editorial
Comment

MeSH terms

Coronary Artery Disease* / drug therapy
Cyclic Nucleotide Phosphodiesterases, Type 5
Erectile Dysfunction*
Humans
Male
Phosphodiesterase 5 Inhibitors
Sildenafil Citrate

Substances

Phosphodiesterase 5 Inhibitors
Sildenafil Citrate
Cyclic Nucleotide Phosphodiesterases, Type 5